Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898832 | 0.79 | GRM5 (0.52) | GRM5POLBSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL852762 | 0.79 | GRM5 (0.52) | GRM5POLBSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL20270834 | 0.78 | SMN1; SMN2 (0.31) | POLBTSHRCDC7DBF4SMN1; SMN2 | |
| SCHEMBL6121465 | 0.76 | GRM5 (0.49) | GRM5TSHRKMT2A | |
| SCHEMBL2687297 | 0.74 | GRM5 (0.48) | GRM5POLBTSHRNPC1KMT2A | |
| SCHEMBL853721 | 0.73 | CDC7 (0.43) | GRM5CDC7DBF4KMT2AHPGD | |
| SCHEMBL852779 | 0.73 | ALDH1A1 (0.39) | GRM5KMT2A | |
| SCHEMBL23856226 | 0.71 | CYP1A2 (0.49) | KMT2AMAPTHAO1 | |
| SCHEMBL4871735 | 0.70 | GRM5 (0.54) | GRM5SMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL20269777 | 0.70 | DGAT1 (0.50) | POLBRAB9ANPC1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2260020-B1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2628726-A1 | Hydroxamate-based inhibitors of deacetylases b | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8349883-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349883-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2011-07-28 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-7943652-B2 | Hydroxamate-based inhibitors of deacetylases B | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| EP-2260020-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG | 2009-10-01 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247547-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | GRM5 1283/4885POLB 945/4885TSHR 2192/4885 |
| US-20110183964-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | HDAC1, HDAC11, HDAC3 | GRM5 1283/4885POLB 945/4885TSHR 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.